Marea heads to Phase 2b after updated biomarker data show CV drug’s promise

Elizabeth Cairns

Senior biopharma journalist

Marea Therapeutics said on Wednesday that its lipid-lowering antibody cut both remnant cholesterol levels and remnant triglycerides — both indicators for cardiovascular disease in at-risk patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Marea heads to Phase 2b after updated biomarker data show CV drug’s promise

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

What Vinay Prasad means for CBER, vaccines, drug approvals and more

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

CRISPR Therapeutics' gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Marea heads to Phase 2b af­ter up­dat­ed bio­mark­er da­ta show CV drug’s promise

Senior biopharma journalist

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Marea heads to Phase 2b after updated biomarker data show CV drug’s promise